Effect of two oral doses of 17β‐estradiol associated with dydrogesterone on thrombin generation in healthy menopausal women: a randomized double‐blind placebo‐controlled study

Oral hormone therapy is associated with an increased risk of venous thrombosis. Drug agencies recommend the use of the lowest efficient dose to treat menopausal symptoms for a better risk/ratio profile, although this profile has not been totally investigated yet. The aim of the study was to compare the effect of the standard dose of 17β‐estradiol to a lower one on thrombin generation (TG).

[1]  G. Badger,et al.  Effects of Oral and Transdermal Hormonal Contraception on Vascular Risk Markers: A Randomized Controlled Trial , 2008, Obstetrics and gynecology.

[2]  R. van Oerle,et al.  Coagulation factors and the protein C system as determinants of thrombin generation in a normal population , 2007, Journal of thrombosis and haemostasis : JTH.

[3]  F. Rosendaal,et al.  Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography , 2007, Thrombosis and Haemostasis.

[4]  P. Sandset,et al.  Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system , 2007, Thrombosis and Haemostasis.

[5]  A. Pines,et al.  IMS Updated Recommendations on postmenopausal hormone therapy , 2007, Climacteric : the journal of the International Menopause Society.

[6]  A. Dei Cas,et al.  Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study. , 2007, Thrombosis research.

[7]  P. Sandset,et al.  Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. , 2007, Thrombosis and haemostasis.

[8]  L. Sandvik,et al.  Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. , 2006, Maturitas.

[9]  P. Kenemans,et al.  Less Effect of Intranasal Than Oral Hormone Therapy on Factors Associated With Venous Thrombosis Risk in Healthy Postmenopausal Women , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[10]  M. R. Toloi,et al.  Hormone replacement therapy and hemostasis: effects in Brazilian postmenopausal women. , 2005, Maturitas.

[11]  F. Depasse,et al.  Towards a standardization of thrombin generation assessment: The influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay , 2005, Thrombosis journal.

[12]  R. Lindsay,et al.  Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. , 2005, Thrombosis research.

[13]  R. Prentice,et al.  Estrogen plus progestin and risk of venous thrombosis. , 2004, JAMA.

[14]  K. Koh,et al.  Effects of Conventional or Lower Doses of Hormone Replacement Therapy in Postmenopausal Women , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[15]  K. Koh,et al.  Significant Differential Effects of Hormone Therapy or Tibolone on Markers of Cardiovascular Disease in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[16]  Dominique Mottier,et al.  Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal Women: A Randomized Trial , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[17]  H. Coenraad Hemker,et al.  Calibrated Automated Thrombin Generation Measurement in Clotting Plasma , 2003, Pathophysiology of Haemostasis and Thrombosis.

[18]  J. Stephenson.  FDA Orders Estrogen Safety Warnings , 2003 .

[19]  J. Stephenson.  FDA orders estrogen safety warnings: agency offers guidance for HRT use. , 2003, JAMA.

[20]  C. Stehouwer,et al.  Increased resistance to activated protein C after short‐term oral hormone replacement therapy in healthy post‐menopausal women , 2002, British journal of haematology.

[21]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[22]  A. Ayhan,et al.  Effects of hormone replacement on hemostasis in spontaneous menopause , 2001, Menopause.

[23]  H. Arnesen,et al.  Increased Risk of Recurrent Venous Thromboembolism during Hormone Replacement Therapy , 2000, Thrombosis and Haemostasis.

[24]  E. Vittinghoff,et al.  Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study , 2000, Annals of Internal Medicine.

[25]  H. Teede,et al.  Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[26]  K. Mann,et al.  "Normal" thrombin generation. , 1999, Blood.

[27]  P. Morange,et al.  Screening for identified and unidentified protein C pathway defects by the Agkistrodon contortrix venom test in consecutive patients. , 1999, American journal of clinical pathology.

[28]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[29]  M. Aiach,et al.  Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[30]  F. Sacks,et al.  Coagulation activation following estrogen administration to postmenopausal women. , 1992, Thrombosis and haemostasis.

[31]  S. Williams,et al.  Dose-dependent effects of postmenopausal estrogen and progestin on antithrombin III and factor XII. , 1988, The Journal of laboratory and clinical medicine.

[32]  A. Imbriano.  [Blood coagulation]. , 1955, La Semana medica.